MediWound Ltd. (MDWD)
Stock Price:
$3.36 USD
-0.22 (-6.15%)
Updated Aug 12, 2020 1:11 PM EDT - Market open
Key Info
| Market Cap |
91.43M |
| Revenue (ttm) |
19.05M |
| Net Income (ttm) |
4.96M |
| Shares Out |
27.21M |
| EPS (ttm) |
-0.34 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 12, 2020 |
| Last Price |
$3.36 |
| Previous Close |
$3.58 |
| Change ($) |
-0.22 |
| Change (%) |
-6.15% |
| Day's Open |
3.60 |
| Day's Range |
3.34 - 3.65 |
| Day's Volume |
116,927 |
| 52-Week Range |
1.44 - 4.44 |
More Stats
| Market Cap |
91.43M |
| Enterprise Value |
64.73M |
| Earnings Date (est) |
Nov 12, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
27.21M |
| Float |
17.12M |
| EPS (basic) |
0.18 |
| EPS (diluted) |
-0.34 |
| FCF / Share |
0.28 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
8.20% |
| Payout Ratio |
n/a |
| Shares Short |
41,948 |
| Short Ratio |
0.65 |
| Short % of Float |
0.83% |
| Beta |
1.63 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
12.20 |
| PS Ratio |
4.80 |
| PB Ratio |
9.61 |
| Revenue |
19.05M |
| Operating Income |
4.49M |
| Net Income |
4.96M |
| Free Cash Flow |
7.50M |
| Net Cash |
26.70M |
| Net Cash / Share |
0.98 |
| Gross Margin |
104.69% |
| Operating Margin |
23.59% |
| Profit Margin |
15.60% |
| FCF Margin |
39.36% |
| ROA |
-14.21% |
| ROE |
-85.11% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (4)
| Buy |
4 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$6.62*
(97.02% upside)
Low
5.50
Current: $3.36
High
7.00
Target: 6.62
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|
| Revenue | 31.79 | 3.40 | 2.50 | 1.56 | 0.60 | 0.26 | - | - | - |
| Revenue Growth | 834.7% | 36.26% | 60.21% | 159.23% | 132.05% | - | - | - | - |
| Gross Profit | 19.94 | 1.31 | 0.92 | -0.60 | -1.92 | -2.53 | - | - | - |
| Operating Income | 4.49 | -3.96 | -13.69 | -20.16 | -21.23 | -21.43 | -7.58 | -2.73 | -4.29 |
| Net Income | 4.96 | -1.06 | -22.15 | -18.89 | -22.09 | -18.88 | -15.35 | 10.94 | -6.17 |
| Shares Outstanding | 27.18 | 27.05 | 21.93 | 21.85 | 21.55 | 20.40 | 20.40 | - | - |
| Earnings Per Share | 0.18 | -0.04 | -0.95 | -0.86 | -1.02 | -0.95 | -0.98 | 0.64 | -0.39 |
| Operating Cash Flow | 8.29 | -12.15 | -16.46 | -16.45 | -19.60 | -16.49 | -9.74 | -4.73 | -2.96 |
| Capital Expenditures | -0.79 | -0.52 | -1.05 | -0.67 | -0.38 | -0.37 | -0.27 | -0.06 | -0.76 |
| Free Cash Flow | 7.50 | -12.68 | -17.50 | -17.12 | -19.98 | -16.86 | -10.01 | -4.79 | -3.72 |
| Cash & Equivalents | 29.28 | 23.54 | 36.07 | 30.03 | 45.77 | 64.85 | 9.55 | 0.34 | 0.00 |
| Total Debt | 2.58 | 0.15 | - | - | - | - | - | 1.56 | - |
| Net Cash / Debt | 26.70 | 23.40 | 36.07 | 30.03 | 45.77 | 64.85 | 9.55 | -1.22 | 0.00 |
| Assets | 40.59 | 35.28 | 44.14 | 35.76 | 52.52 | 71.12 | 14.83 | 25.44 | - |
| Liabilities | 25.42 | 26.30 | 34.52 | 27.99 | 29.05 | 28.25 | 34.63 | 9.80 | - |
| Book Value | 15.17 | 8.97 | 9.62 | 7.77 | 23.47 | 42.87 | -19.80 | 15.63 | - |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
MediWound Ltd. |
| Country |
Israel |
| Employees |
74 |
| CEO |
Sharon Malka |
Stock Information
| Ticker Symbol |
MDWD |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: MDWD |
| IPO Date |
March 20, 2014 |
Description
MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MWPC003 for connective tissue disorders. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.